(Credit: Karolina Grabowska from Pexels)
ANN ARBOR, Mich. — A recent study reveals that the Inflation Reduction Act (IRA) could save Medicare beneficiaries over $7,000 per year on out-of-pocket costs for common oral cancer medications. This significant reduction in expenses comes as a relief to many patients who have long struggled with the financial burden of cancer treatment.
The study, published in JAMA Network Open, analyzed the potential impact of the IRA on out-of-pocket spending for nine popular oral cancer drugs. Researchers found that the average annual savings for patients could reach $7,260 in 2024, with some individuals saving nearly $10,000 on a single medication.
The Inflation Reduction Act, enacted in August 2022, includes provisions aimed at reducing prescription drug costs for Medicare beneficiaries. One of its key features is a new cap on out-of-pocket spending for outpatient prescription drugs covered under Medicare Part D plans. This cap is set at approximately $3,500 for 2024 and will further decrease to $2,000 in 2025.
To put this into perspective, consider a patient prescribed venetoclax, a medication used to treat certain types of leukemia and lymphoma. In 2023, this patient might have paid an average of $13,682 out-of-pocket for a year’s supply. Under the new law, their costs in 2024 would drop to $3,913 – a staggering savings of $9,769.
The study examined nine commonly prescribed oral cancer medications, including drugs used to treat prostate cancer, leukemia, and lung cancer. Researchers used the online Medicare Part D Plan Finder to compare estimated out-of-pocket costs for these medications in 2023 and 2024, based on plans available in Ann Arbor, Michigan.
The results were striking. In 2023, the mean out-of-pocket cost for these medications was $11,284 per year. In 2024, under the new IRA provisions, that average drops to $3,927 – a reduction of nearly 65%.
This dramatic decrease in costs could have far-reaching implications for cancer patients. Previous research has shown that high out-of-pocket expenses often lead to lower medication adherence, increased hospitalization rates, and even higher mortality. Cancer patients are particularly vulnerable to financial distress and medical debt, with many forced to choose between their treatment and other essential expenses.
The potential impact of the IRA extends beyond just the nine drugs studied. Experts estimate that the $2,000 cap on out-of-pocket drug spending (which will be in effect from 2025 onward) could benefit approximately 1.5 million Medicare Part D beneficiaries, based on 2021 data.
While the study’s findings are promising, the researchers caution that their analysis has some limitations. The cost estimates are based on a single zip code and may not perfectly represent costs in other areas. Additionally, actual out-of-pocket expenses could differ due to factors like supplemental coverage or specific pharmacy distribution channels.
Nevertheless, this research provides compelling evidence that legislative action can effectively lower patient costs for essential medications. As policymakers consider extending similar protections to patients with commercial insurance, understanding the magnitude of these potential savings becomes crucial.
“People with cancer are already vulnerable to financial distress and medical debt. Our analysis suggests that legislative policy can have a big impact on the cost of cancer care. This is especially critical as lawmakers now consider extending an out-of-pocket cap to commercial insurance,” says lead study author Dr. Benjamin Pockros, a urology resident at Michigan Medicine, in a statement.
For cancer patients and their families, the Inflation Reduction Act offers a glimmer of hope in the often-overwhelming landscape of treatment costs. As we move into 2025 and beyond, millions of Medicare beneficiaries may find that their life-saving medications are finally within financial reach, allowing them to focus on their health rather than their bank accounts.
Paper Summary
Methodology
The researchers used the Medicare.gov website and its Plan Finder tool to look up the costs of nine specific oral cancer medications. These drugs were chosen because they were among the top 10 most expensive oral cancer drugs covered by Medicare Part D in 2020.
The researchers entered a zip code for Ann Arbor, Michigan (48103) and recorded the estimated out-of-pocket costs for each drug under all available Medicare Part D plans in that area for both 2023 and 2024. This process allowed them to compare how much patients might pay before and after the Inflation Reduction Act’s provisions take effect.
Key Results
The study found substantial cost reductions across all nine medications examined. The mean out-of-pocket cost for these drugs in 2023 was $11,284. In 2024, that average drops to $3,927 – a savings of $7,357 per year. The medication with the largest savings was venetoclax, with patients potentially saving $9,769 annually. Even the drug with the smallest savings, enzalutamide, still showed a significant reduction of $5,719 per year. These results were consistent across all the Medicare Part D plans available in the selected zip code.
Study Limitations
The researchers acknowledge several limitations to their study. First, they only looked at plans available in one zip code, which may not perfectly represent costs nationwide. Second, the cost data came from an online database and might not account for all real-world factors that could affect a patient’s out-of-pocket expenses, such as additional insurance coverage or specific pharmacy arrangements. Lastly, the study focused on just nine medications, which, while significant, don’t represent all cancer drugs or other expensive medications that patients might need.
Discussion & Takeaways
The researchers emphasize that these findings highlight the potential for legislative action to significantly impact healthcare costs. They suggest that the savings from the Inflation Reduction Act could improve medication adherence and reduce the financial stress associated with cancer treatment. The study also points out that similar cost-saving measures could potentially benefit patients with other types of insurance. The authors argue that understanding the magnitude of these savings is crucial as policymakers consider expanding such protections to more Americans.
Funding & Disclosures
The study was supported by grants from the University of Michigan Institute for Health Policy and Innovation, the National Cancer Institute, and the National Institutes of Health. One of the authors, Dr. Stensland, reported receiving these grants during the conduct of the study. No other conflicts of interest were disclosed by the authors.
